Researchers at Karolinska Institutet in Sweden have studied the incidence and regional distribution of Alzheimer’s disease biomarkers in the brains of people with Down’s syndrome. The results can bring new possibilities for earlier diagnosis and preventive treatment of dementia. The study is published in Molecular Neurodegeneration.
While medical advances and life quality improvements have increased the life expectancy of people with Down’s syndrome to an average of 60 years, up to 90% develop Alzheimer’s disease if they live long enough.
In Alzheimer’s disease, clumps of amyloid form plaques around the neurons of the brain,…
